At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

The Phase 1 trial ANQUR, now testing two new doses of the ALS therapy QRL-201, is enrolling patients at 12 sites in Canada and across Europe.

Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...

In some cases, however, brains outlast all other soft tissues and remain intact for hundreds or thousands of years.

Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...

Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after assuming coverage of the ...

At Lenovo Tech World ’24, global technology leader Lenovo and the Scott-Morgan Foundation (SMF), a non-profit pioneering ...

Scientists studied 188 people related to someone with ALS caused by a C9ORF72 mutation to identify markers of disease risk in ...

PTC Therapeutics faces significant risks with its key revenue sources, Translarna and Emflaza. Find out why I am sticking ...

Thompson, who has spent the latter part of his coaching career while suffering from ALS, is much more than a fine football ...

We recently published a list of 10 Cheapest Stocks to Buy On Robinhood. In this article, we are going to take a look at where ...

Genzyme Corp. (Sanofi Genzyme) has identified receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of Alzheimer’s disease, multiple ...